Abstract
Osteosarcoma (OS) is the most frequent primary bone malignancy and affects adolescents and young adults. Recently dysregulation of miRNAs has received more attention because of its extensive role in OS carcinogenesis. This research was designed to verify how microRNA-93 (miR-93) and tissue inhibitor of matrix metalloproteinase 2 (TIMP2) be involved in OS development. At first, the levels of miR-93 and its predictive target gene TIMP2 were detected in OS and osteoblast cell lines, and 62 pairs OS and adjacent non-OS specimens by real-time PCR and western blot. Then, viability, invasion, and epithelial mesenchymal transition (EMT) of OS cell lines were examined when overexpressed or knocked down miR-93, or overexpressed TIMP2. Finally, the interaction between miR-93 and TIMP2 was evaluated using mutation, gain, and loss experiment. Our data indicated that miR-93 was increased while TIMP2 was decreased in both OS cell lines and tissues. MiR-93 high-expression and TIMP2 low-expression were related with poor overall survival and prognosis of OS patients. Overexpression or knockdown experiment indicated that miR-93 enhanced OS cell viability, invasion, and EMT expression. TIMP2 could inhibit OS cell viability, invasion, and EMT expre...Continue Reading
References
Jul 31, 2003·Cell·Dong-Wan SeoWilliam G Stetler-Stevenson
Jan 28, 2004·Cell·David P Bartel
Mar 15, 2006·Cancer·Bridget F KoontzEdward C Halperin
Sep 19, 2009·Nature Reviews. Genetics·Carlo M Croce
Dec 22, 2009·The Lancet Oncology·Joanne Weidhaas
Mar 6, 2010·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Richard Gorlick, Chand Khanna
Oct 1, 2011·Cellular Oncology (Dordrecht)·Luisa MontaniniMaria Serena Benassi
Oct 23, 2012·Pharmacology & Therapeutics·Patrick J Grohar, Lee J Helman
Feb 19, 2013·Cytokine·E I BraicuJ Sehouli
Oct 16, 2014·Genome Biology·S Nana-Sinkam, Carlo M Croce
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael S IsakoffRichard Gorlick
Dec 3, 2015·Current Opinion in Pediatrics·Michael W BishopRichard Gorlick
Mar 24, 2016·Oncotarget·Jing LiYa Zhang
Jun 1, 2016·Anti-cancer Drugs·Yan SuWenqi Song
Jun 30, 2016·Drug Discovery Today·Hanneke I VosDunja Maroeska W M Te Loo
Dec 10, 2016·Rheumatology and Therapy·Brock A LindseyEugenie S Kleinerman
Mar 25, 2017·Nature Reviews. Endocrinology·D Matthew GianferanteSharon A Savage
Jun 18, 2017·Scientific Reports·Xiaoqing YiZehua Wang
Dec 9, 2017·PloS One·Hao GuanShaoying Lu
May 9, 2016·Mycology·Hui SunXuejun Jiang
Sep 3, 2018·Gene·Lei WangYu Chao
Nov 21, 2018·Urologic Oncology·Hua JiangAibin Wu
Dec 14, 2018·International Journal of Biological Macromolecules·Ke YangHao-Yu Zou
Dec 24, 2018·OncoTargets and Therapy·Fengfeng XuJian Ao
Dec 26, 2018·OncoTargets and Therapy·Jianping GuoFajia Wang
Citations
Feb 13, 2020·Scientific Reports·Divya NivedithaShibasish Chowdhury
Feb 28, 2020·International Journal of Genomics·Peng LiWenshuai Zhu
Aug 18, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Zhi Xiong ChongWan Yong Ho